Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek February 2, 2004	Microvision Puts A Scanner On Your Cap Microvision, a leader in scanners, keeps luring big customers. CEO Richard Rutkowski has signed up Honda Motor, Boeing, Stryker, and the U.S. Army. Microvision makes Nomad, an enhanced-vision system mounted on a baseball cap. It uses a scanning mirror and a beam of light to project images on the user's retina.
The Motley Fool May 2, 2011 Anupama Pattanaik	J&J Attempts to Create Major "Synthes"-is Johnson & Johnson will acquire the medical device maker for $21.3 billion.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward.
The Motley Fool May 20, 2011 Andrea Kalvesmaki	Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings.
The Motley Fool July 26, 2005 Rich Smith	J&J: One Pricey Stock This giant of the health-care world reported its second quarter 2005 earnings last week but, by all appearances, failed to impress Wall Street. Johnson & Johnson's become very big, very pricey.
The Motley Fool April 29, 2011 David Williamson	Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes.
The Motley Fool January 20, 2004 Alyce Lomax	Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings.
The Motley Fool January 28, 2011 Anand Chokkavelu	10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo.
The Motley Fool June 26, 2006 Stephen D. Simpson	J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note.
The Motley Fool December 31, 2007 Brian Orelli	Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008.
The Motley Fool March 24, 2011 Anand Chokkavelu	Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."
The Motley Fool January 12, 2006 Stephen D. Simpson	The Guidant Auction Continues Johnson & Johnson hopes to save the deal with a last-minute raise of its offer. Although Boston Scientific's offer is $4 per share higher, that doesn't necessarily make it the best value. Investors, take note.
Chemistry World October 1, 2014 Phillip Broadwith	J&J to buy antiviral specialist Alios Johnson and Johnson has agreed to buy antiviral specialist Alios BioPharma for $1.75 billion
The Motley Fool September 24, 2010 Anand Chokkavelu	10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list
The Motley Fool September 28, 2009 Brian Orelli	The Berkshire of Health Care Johnson & Johnson is becoming the Berkshire Hathaway of health care. In addition to its usual M.O. of bolt-on acquisitions, the health-care giant has recently taken some equity stakes in smaller drug companies.
BusinessWeek April 17, 2006 Amy Barrett	Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created.
The Motley Fool August 24, 2010 Matt Koppenheffer	How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale?
BusinessWeek December 20, 2004 Amy Barrett	J&J: Don't Stop Dealmaking Now For years, health-care giant Johnson & Johnson has held on-again, off-again acquisition talks with medical-device maker Guidant Corp. But now, patent expirations and a thin pipeline mean the giant needs more than just Guidant.
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock.
The Motley Fool November 26, 2007 Brian Orelli	Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly.
The Motley Fool November 3, 2005 Stephen D. Simpson	The At-Odds Couple Johnson & Johnson seems to want out, but Guidant looks willing to grab the shotgun to see that this union is completed. Investors, should the deal fall through, look for J&J to continue shopping and don't be surprised if Guidant attracts attention from Abbott Labs or Boston Scientific.
The Motley Fool October 7, 2010 Anand Chokkavelu	How Johnson & Johnson Really Makes Money Hint: It's not Tylenol.
The Motley Fool April 13, 2004 Alyce Lomax	J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter.
BusinessWeek February 26, 2007 Gene G. Marcial	Microvision's Gleam Lights Up A Big Screen "The mini projectors created tremendous buzz," says Peter Conley, managing director at MDB Capital Group.
The Motley Fool September 25, 2009 Brian Orelli	Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK.
BusinessWeek January 30, 2006 Robert Barker	Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber.
The Motley Fool October 26, 2011	A Brief History of Johnson & Johnson's Returns J&J shares are much more reasonably valued today than they were ten years ago; shareholders are unlikely to experience the same going forward.
The Motley Fool March 11, 2011 Brian Orelli	Johnson & Johnson Gets a Slap on the Wrist The consent decree could have been a lot worse.
The Motley Fool January 24, 2006 Stephen D. Simpson	Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did.
The Motley Fool February 22, 2011 Rich Smith	Investors Dump MicroVision. Are They Right? An earnings warning kills the stock.
BusinessWeek October 10, 2005	J&J: How A Dealmaker Nurtures Newcomers Johnson & Johnson has a good track record for retaining employees after a takeover. The company's broadly decentralized structure, which gives managers great leeway - no small thing for execs used to running their own shows.
BusinessWeek April 17, 2006 Amy Barrett	J&J: Reinventing How It Invents Johnson & Johnson bets on a new push for product development as a cure for its ailing stock.
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull There are many ways to expose one's portfolio to the health-care industry. But J&J offers the best upside potential at relatively little risk.
The Motley Fool September 17, 2010 James Early	Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care.
The Motley Fool November 22, 2006 Brian Lawler	Dueling Fools: Johnson & Johnson Bear Rebuttal The bottom line is that investors are putting their faith in the ability of J&J's management to acquire its way to renewing top-line growth in the coming years.
The Motley Fool June 30, 2006 Stephen D. Simpson	Johnson & Johnson: This Is More Like It Filling out the drug and device businesses will be good for growth. Investors, take note.
BusinessWeek June 18, 2007 Arlene Weintraub	Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific.
The Motley Fool December 6, 2007 Brian Orelli	An Unlikely Chat With Your Doctor J&J starts direct-to-consumer advertising of its drug-eluting stent. Can it really pay off?
The Motley Fool January 26, 2005 Rich Smith	J&J: Dialing for Dollars It pays to be big in a weak dollar world. Just ask Johnson & Johnson. Still, in the year to come, investors will want to keep one eye on J&J's operational performance, and the other on the U.S. Dollar's exchange rates against foreign currencies.
The Motley Fool January 2, 2008 Brian Orelli	Congestion in the OTC Market J&J already has generic competition for its new drug Zyrtec.
The Motley Fool September 11, 2010 Anand Chokkavelu	How Much of a Bargain Is Johnson & Johnson Stock Right Now? Let's take a look to see how cheap shares of Johnson & Johnson are trading, how consistent its performance has been, and what kind of growth profile it has -- both on an absolute and a relative basis.
The Motley Fool October 12, 2007 Billy Fisher	Dueling Fools: Johnson & Johnson Bear The bearish opinion on J&J is that it is an impressive company that may have its best days behind it.
The Motley Fool October 12, 2004 Alyce Lomax	Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson?
Bio-IT World March 2006 Mike May	The Evolving Grid Computing System at J&J Johnson & Johnson is planning to double the size of its grid computing network and the number of applications that run on it by the end of this year, according to company executives.
The Motley Fool April 16, 2008 Brian Orelli	Johnson & Johnson Chugs Along Strong growth, mostly from the weak dollar, fails to excite Johnson & Johnson's investors.
The Motley Fool October 14, 2008 Brian Orelli	Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.
The Motley Fool July 17, 2007 Ryan Fuhrmann	Diagnosing J&J's Product Diversity Health-care giant Johnson & Johnson's blues may indicate trouble ahead for competitors. Investors, take note.
The Motley Fool June 25, 2010 Brian Orelli	The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error.
The Motley Fool April 13, 2006 Doug Short	A Foolish Baby Shower: Johnson & Johnson If you're an advocate of these two rules -- "It's never too early to start investing" and "Invest in what you know" -- then here is an ideal pick for baby's first stock.